Factors Associated With Decision Making In the Second-Line Treatment of Patients With Advanced/Metastatic Gastrointestinal Cancers
Podcast 2: Next steps after progression in GEJ cancers: Rechallenging with VEGF-directed therapy
Post-Test/Evaluation

Questions marked with a * are required

18%

Contact Information

First Name

Last Name

Email Address

Credentials/Degree (MD, DO, RN, etc.)

Date of Participation

Edward is a 75 year-old man who presents with an ulcerating mass in the gastric body that is HER2+ and has progressed despite being on first-line therapy. Which of the following are options is most appropriate as second-line therapy?

A. Ramucirumab

B. Tipiracil/trifluridine

C. Trastuzumab deruxtecan

D. Entrectinib

Follow-up imaging finds new metastatic lesions in the liver. Which of the following statements are true regarding therapy sequencing?

A. Antiangiogenic therapy has no role in second- or third-line therapy for HER2+ cancers

B. Trifluridine/tipiracil therapy should be considered as a third-line treatment option

C. Paclitaxel + ramucirumab is a proven superior second-line treatment option

D. Multidisciplinary care teams do not help maximize outcomes after first-line therapy has failed